CIK 1842545
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 57.40% | 14 |
| Unclassified | 14.77% | 4 |
| Health Care Providers & Services | 13.72% | 3 |
| Health Care Equipment & Supplies | 6.83% | 3 |
| Life Sciences Tools & Services | 4.85% | 1 |
| Software & IT Services | 2.43% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | ARGX | Argenx SE | Health Care | 11.70% |
| 2 | ICLR | ICON PLC | Unclassified | 8.33% |
| 3 | INSM | INSMED Inc | Health Care | 7.70% |
| 4 | GH | Guardant Health, Inc. | Health Care | 6.02% |
| 5 | BMRN | BIOMARIN PHARMACEUTICAL INC | Health Care | 6.00% |
| 6 | NTRA | Natera, Inc. | Health Care | 5.12% |
| 7 | SRRK | Scholar Rock Holding Corp | Health Care | 5.10% |
| 8 | ILMN | ILLUMINA, INC. | Health Care | 4.85% |
| 9 | TERNS PHARMACEUTICALS INC | Unclassified | 4.57% | |
| 10 | BBIO | BridgeBio Pharma, Inc. | Health Care | 4.16% |
22/26 names classified · sector 85.2% of weight · industry 85.2% · mkt cap 69.4%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 85.2% of the book is sector-classified (unclassified names shown, never dropped).
Only 19% of book weight classified — the grid is NOT representative of the whole book.
Classified: 19.3% of book weight (6/25 names) · unclassified 80.7%: ARGX, ICLR, INSM, , GH, NTRA, SRRK, BBIO, ASND, PTGX +9 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | ARGXARGENX SE | 76,336 | $56M | 11.7% | ADD 22% |
| 2 | ICLRICON PLC | 358,500 | $40M | 8.3% | ADD 45% |
| 3 | INSMINSMED INC | 224,271 | $37M | 7.7% | ADD 6% |
| 4 | GHGUARDANT HEALTH INC | 310,281 | $29M | 6.0% | ADD 9% |
| 5 | BMRNBIOMARIN PHARMACEUTICAL INC | 505,809 | $29M | 6.0% | ADD 38% |
| 6 | NTRANATERA INC | 121,877 | $24M | 5.1% | TRIM −33% |
| 7 | SRRKSCHOLAR ROCK HLDG CORP | 494,019 | $24M | 5.1% | ADD 36% |
| 8 | ILMNILLUMINA INC | 187,413 | $23M | 4.9% | TRIM −19% |
| 9 | TERNS PHARMACEUTICALS INC | 412,497 | $22M | 4.6% | ADD 50% |
| 10 | BBIOBRIDGEBIO PHARMA INC | 267,031 | $20M | 4.2% | ADD 3% |
| 11 | ASNDASCENDIS PHARMA A/S | 86,650 | $20M | 4.2% | NEW |
| 12 | PTGXPROTAGONIST THERAPEUTICS INC | 179,322 | $19M | 4.0% | ADD 213% |
| 13 | RAREULTRAGENYX PHARMACEUTICAL IN | 884,121 | $19M | 3.9% | NEW |
| 14 | BSXBOSTON SCIENTIFIC CORP | 293,152 | $18M | 3.9% | NEW |
| 15 | FTREFORTREA HLDGS INC | 1,307,560 | $12M | 2.6% | ADD 7% |
| 16 | KYMRKYMERA THERAPEUTICS INC | 145,816 | $12M | 2.5% | ADD 7% |
| 17 | PRCTPROCEPT BIOROBOTICS CORP | 483,815 | $12M | 2.5% | ADD 57% |
| 18 | RVMDREVOLUTION MEDICINES INC | 119,464 | $12M | 2.4% | ADD 3% |
| 19 | TEMTEMPUS AI INC | 256,269 | $12M | 2.4% | NEW |
| 20 | CMPSCOMPASS PATHWAYS PLC | 2,060,427 | $11M | 2.4% | ADD 36% |
| 21 | CENTESSA PHARMACEUTICALS PLC | 214,291 | $9M | 1.8% | ADD 108% |
| 22 | ALKSALKERMES PLC | 238,673 | $8M | 1.8% | ADD 192% |
| 23 | ATAIATAIBECKLEY INC | 1,709,359 | $6M | 1.3% | NEW |
| 24 | ISRGINTUITIVE SURGICAL INC | 4,390 | $2M | 0.4% | HOLD |
| 25 | IMCRIMMUNOCORE HLDGS PLC | 46,300 | $1M | 0.3% | HOLD |
| 26 | PCSCPERCEPTIVE CAP SOLUTIONS COR | 37,686 | $413,415 | 0.1% | NEW |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| ARGXARGENX SE | 75K | 75K | 77K | 77K | 63K | 76K | $56M |
| ICLRICON PLC | 209K | 209K | 203K | 183K | 247K | 359K | $40M |
| INSMINSMED INC | 514K | 443K | 429K | 272K | 211K | 224K | $37M |
| GHGUARDANT HEALTH INC | — | — | 212K | 284K | 284K | 310K | $29M |
| BMRNBIOMARIN PHARMACEUTICAL INC | 419K | 383K | 367K | 367K | 367K | 506K | $29M |
| NTRANATERA INC | 340K | 280K | 236K | 204K | 183K | 122K | $24M |
| SRRKSCHOLAR ROCK HLDG CORP | — | — | 269K | 363K | 363K | 494K | $24M |
| ILMNILLUMINA INC | 343K | 343K | 343K | 322K | 231K | 187K | $23M |
| TERNS PHARMACEUTICALS INC | — | — | — | — | 275K | 412K | $22M |
| BBIOBRIDGEBIO PHARMA INC | — | — | 259K | 259K | 259K | 267K | $20M |
| ASNDASCENDIS PHARMA A/S | — | 57K | — | — | — | 87K | $20M |
| PTGXPROTAGONIST THERAPEUTICS INC | — | — | — | — | 57K | 179K | $19M |
| RAREULTRAGENYX PHARMACEUTICAL IN | 628K | 628K | 628K | 697K | — | 884K | $19M |
| BSXBOSTON SCIENTIFIC CORP | — | — | — | — | — | 293K | $18M |
| FTREFORTREA HLDGS INC | — | — | — | 989K | 1.2M | 1.3M | $12M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
